Diabetic Peripheral Neuropathy News and Research

RSS
According to the National Institute of Diabetes & Digestive & Kidney Diseases, approximately half of those with diabetes have some form of nerve damage, or neuropathy, but not all will develop symptoms. While nerve problems can occur at any time, the highest rates are among those who have had diabetes for at least 25 years. People who have had problems controlling their blood sugar levels, have high blood pressure, are overweight, have high levels of blood fat, or are over the age of 40, may also have a greater risk of developing diabetic peripheral neuropathy. Symptoms can include numbness, tingling or pain and weakness in the toes, feet, legs, hands, arms and fingers. These symptoms are often worse at night.
First consensus guidelines for use of neurostimulation in chronic pain

First consensus guidelines for use of neurostimulation in chronic pain

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

Diabetic peripheral neuropathy risk highlighted in children

Diabetic peripheral neuropathy risk highlighted in children

Gait abnormalities found in diabetic neuropathy

Gait abnormalities found in diabetic neuropathy

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

Medical devices for diabetic peripheral neuropathy: an interview with Dr. Shai Gozani, CEO of NeuroMetrix

Medical devices for diabetic peripheral neuropathy: an interview with Dr. Shai Gozani, CEO of NeuroMetrix

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

OSA independently linked with DPN in patients with type 2 diabetes mellitus

OSA independently linked with DPN in patients with type 2 diabetes mellitus

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

New study into pain associated with diabetes

New study into pain associated with diabetes

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

U-M researchers to study new approach in halting downward spiral of diabetes

U-M researchers to study new approach in halting downward spiral of diabetes

NeuroMetrix second quarter total revenues decrease to $2.6 million

NeuroMetrix second quarter total revenues decrease to $2.6 million

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease